Companies
Major investors unconcerned about GSK’s lack of payout for mother and baby home survivors
Some smaller sustainability specialists are engaging with the pharmaceutical giant but there is unlikely to be a major fallout
Major institutional investors are not taking issue with GlaxoSmithKline (GSK) on its approach to victims of mother and baby homes because of its complicated role and the lack of any legal or monetary ramification.
This month the Irish government is due to launch an €800 million compensation scheme for the 34,000 survivors of Catholic institutions. However, despite the pharmaceutical giant having an involvement in the trials that were held at the homes without consent, they ...